{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:04:55Z","timestamp":1793405095068,"version":"4.5.0"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"\n Importance<\/jats:title>\n Treating opioid use disorder (OUD) in pregnancy with sublingual buprenorphine is an evidence-based practice, but it has disadvantages that could be addressed with an extended-release formulation.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the effectiveness and safety of extended-release buprenorphine vs sublingual buprenorphine for OUD in pregnancy through 12 months post partum.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This 2-group, open-label, noninferiority, randomized clinical trial was conducted between July 2, 2020, and October 30, 2024, among adults with OUD and a singleton pregnancy of 6 to 30 weeks\u2019 gestational age at 13 outpatient cross-disciplinary peripartum OUD treatment sites.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Randomization to sublingual or extended-release buprenorphine (weekly formulation during pregnancy, monthly formulation optional post partum if not breastfeeding).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary and key secondary outcomes were illicit opioid abstinence during pregnancy and the postpartum period, respectively, defined as the proportion of weekly collected urine samples negative for illicit opioids. If noninferiority was demonstrated at a margin of 0.15, testing for superiority was planned. Key secondary infant outcomes from medical records were opioid treatment for neonatal opioid withdrawal syndrome (NOWS; yes or no) and number of opioid treatment days for NOWS.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 140 randomized participants, the mean (SD) age was 31.2 (4.6) years. There were 10 Black participants (7.1%), 10 Hispanic participants (7.1%), 116 (82.9%) White participants, and 14 participants (10.0%) who belonged to additional groups. All but 2 were already prescribed sublingual buprenorphine. Study completion was 98% through pregnancy (137 participants) and 81% through 12 months post partum (114 participants). Illicit opioid abstinence was higher during pregnancy for participants receiving extended-release vs sublingual buprenorphine (82.5% vs 72.6%; mean difference, 9.84 [95% CI, 1.72 to 17.95] percentage points;\n P<\/jats:italic>\n \u2009=\u2009.009). Postpartum abstinence rates declined and were similar in both groups (60.2% vs 59.5%; mean difference, 0.65 [98% CI, \u221212.72 to 14.02] percentage points;\n P<\/jats:italic>\n \u2009=\u2009.45). Those receiving extended-release buprenorphine experienced fewer serious adverse events during pregnancy (8.7% vs 26.8%;\n P<\/jats:italic>\n \u2009=\u2009.007) and post partum (6.0% vs 18.6%;\n P<\/jats:italic>\n \u2009=\u2009.04). Nonserious adverse events rates did not differ between groups, but more were deemed medication-related for extended-release participants during pregnancy (26.1% vs 7.0%;\n P<\/jats:italic>\n \u2009=\u2009.003). Infants exposed to extended-release vs sublingual buprenorphine did not differ in need for opioid treatment (30.2% vs 26.5%; relative risk, 1.14 [98% CI, 0.54 to 1.99];\n P<\/jats:italic>\n \u2009=\u2009.64) or mean (SE) treatment days (10.9 [2.2] vs 14.8 [3.0] days; relative risk, 0.73 [98% CI, 0.36 to 1.51];\n P<\/jats:italic>\n \u2009=\u2009.28). At birth, extended-release\u2013exposed neonates had larger mean (SE) head circumferences than those exposed to sublingual buprenorphine (34.0 [0.2] vs 33.4 [0.2] cm; mean difference, 0.63 [95% CI, \u22120.00 to 1.26] cm;\n P<\/jats:italic>\n \u2009=\u2009.049).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings of this randomized clinical trial support weekly extended-release buprenorphine for OUD treatment during pregnancy.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03918850<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamainternmed.2026.0057","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:30:30Z","timestamp":1773675030000},"page":"533","source":"Crossref","is-referenced-by-count":9,"title":["Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum"],"prefix":"10.1001","volume":"186","author":[{"given":"T. John","family":"Winhusen","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio"},{"name":"University of Cincinnati\/UC Health Addiction Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R.","family":"Lofwall","sequence":"additional","affiliation":[{"name":"Departments of Behavioral Science and Psychiatry, Center on Drug and Alcohol Research, University of Kentucky College of Medicine, Lexington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frankie","family":"Kropp","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio"},{"name":"University of Cincinnati\/UC Health Addiction Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio"},{"name":"University of Cincinnati\/UC Health Addiction Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela C.","family":"Smid","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candace","family":"Hodgkins","sequence":"additional","affiliation":[{"name":"Gateway Community Services, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth E.","family":"Krans","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology, and Reproductive Sciences, and Magee-Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Division of Addiction Science, Marshall University, Huntington, West Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisha M.","family":"Wachman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davida M.","family":"Schiff","sequence":"additional","affiliation":[{"name":"Divisions of General Academic Pediatrics and Newborn Medicine, Mass General for Children, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Guille","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Science, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Rudolf","sequence":"additional","affiliation":[{"name":"Addiction Recovery Services, Swedish Medical Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"CODA, Inc, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Leeman","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of New Mexico School of Medicine, Albuquerque"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Lewis","sequence":"additional","affiliation":[{"name":"The Emmes Company, LLC, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail G.","family":"Matthews","sequence":"additional","affiliation":[{"name":"The Emmes Company, LLC, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Cochran","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquie","family":"King","sequence":"additional","affiliation":[{"name":"The Emmes Company, LLC, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Wilder","sequence":"additional","affiliation":[{"name":"Perinatal Addiction Program, University of Cincinnati Health, Cincinnati, Ohio"},{"name":"Now with Hazelden Betty Ford Foundation, Center City, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Rosa","sequence":"additional","affiliation":[{"name":"Center for the Clinical Trials Network, National Institute on Drug Abuse, Bethesda, Maryland (now retired)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"ioi260005r1","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1097\/AOG.0000000000002235","article-title":"Committee opinion No. 711: opioid use and opioid use disorder in pregnancy.","volume":"130","author":"American College of Obstetricians and Gynecologists","year":"2017","journal-title":"Obstet Gynecol"},{"key":"ioi260005r2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jsat.2017.04.017","article-title":"The relationship between diversion-related attitudes and sharing and selling buprenorphine.","volume":"78","author":"Kenney","year":"2017","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"ioi260005r3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","article-title":"A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.","volume":"8","author":"Lofwall","year":"2014","journal-title":"J Addict Med"},{"key":"ioi260005r4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","article-title":"Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.","volume":"144","author":"Greenwald","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"ioi260005r5","doi-asserted-by":"publisher","first-page":"64.e1","DOI":"10.1016\/j.ajog.2016.09.095","article-title":"Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy.","volume":"216","author":"Bastian","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"ioi260005r6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial.","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"2","key":"ioi260005r7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/ADM.0000000000000457","article-title":"Buprenorphine pharmacology review: update on transmucosal and long-acting formulations.","volume":"13","author":"Coe","year":"2019","journal-title":"J Addict Med"},{"issue":"5","key":"ioi260005r8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/ajad.70034","article-title":"Monthly buprenorphine depot injection (SUBLOCADE) for opioid use disorder during pregnancy.","volume":"34","author":"Ramage","year":"2025","journal-title":"Am J Addict"},{"key":"ioi260005r9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejogrb.2024.04.003","article-title":"Extended-release versus oral buprenorphine as opioid maintenance treatment during pregnancy-maternal and neonatal outcomes.","volume":"297","author":"Kanervo","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"ioi260005r10","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/AOG.0000000000004126","article-title":"Subcutaneous buprenorphine extended-release use among pregnant and postpartum women.","volume":"136","author":"Cleary","year":"2020","journal-title":"Obstet Gynecol"},{"issue":"1","key":"ioi260005r11","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3127676","article-title":"Subcutaneous extended-release buprenorphine use in pregnancy.","volume":"2020","author":"Towers","year":"2020","journal-title":"Case Rep Obstet Gynecol"},{"issue":"3","key":"ioi260005r12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/ajad.13518","article-title":"Extended-release buprenorphine in pregnancy.","volume":"33","author":"Hubbell","year":"2024","journal-title":"Am J Addict"},{"issue":"3","key":"ioi260005r13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.14740\/jcgo919","article-title":"What to expect with pregnant or postpartum prescribing of extended-release buprenorphine (CAM2038).","volume":"12","author":"Lofwall","year":"2023","journal-title":"J Clin Gynecol Obstet"},{"key":"ioi260005r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209030","article-title":"Collaborative care programs for pregnant and postpartum individuals with opioid use disorder: organizational characteristics of sites participating in the NIDA CTN0080 MOMs study.","volume":"149","author":"Kropp","year":"2023","journal-title":"J Subst Use Addict Treat"},{"issue":"4","key":"ioi260005r15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.acap.2016.10.003","article-title":"Wide variation found in care of opioid-exposed newborns.","volume":"17","author":"Bogen","year":"2017","journal-title":"Acad Pediatr"},{"issue":"4","key":"ioi260005r16","doi-asserted-by":"publisher","first-page":"e803","DOI":"10.1542\/peds.2015-1141","article-title":"Implementation of a neonatal abstinence syndrome weaning protocol: a multicenter cohort study.","volume":"136","author":"Hall","year":"2015","journal-title":"Pediatrics"},{"issue":"4","key":"ioi260005r17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1001\/jamapediatrics.2017.5195","article-title":"Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis.","volume":"172","author":"MacMillan","year":"2018","journal-title":"JAMA Pediatr"},{"key":"ioi260005r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106014","article-title":"Medication treatment for opioid use disorder in expectant mothers (MOMs): design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations.","volume":"93","author":"Winhusen","year":"2020","journal-title":"Contemp Clin Trials"},{"issue":"9","key":"ioi260005r21","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.2105\/AJPH.84.9.1486","article-title":"The Adequacy of Prenatal Care Utilization Index: its US distribution and association with low birthweight.","volume":"84","author":"Kotelchuck","year":"1994","journal-title":"Am J Public Health"},{"key":"ioi260005r22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.drugalcdep.2014.10.002","article-title":"Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients.","volume":"145","author":"McHugh","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"ioi260005r23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.addbeh.2016.03.028","article-title":"Psychometric evaluation of the 10-item Short Opiate Withdrawal Scale-Gossop (SOWS-Gossop) in patients undergoing opioid detoxification.","volume":"60","author":"Vernon","year":"2016","journal-title":"Addict Behav"},{"key":"ioi260005r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108270","article-title":"A brief telephone-delivered peer intervention to encourage enrollment in medication for opioid use disorder in individuals surviving an opioid overdose: results from a randomized pilot trial.","volume":"216","author":"Winhusen","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"ioi260005r26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The Hospital Anxiety and Depression Scale.","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"ioi260005r27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cct.2018.04.001","article-title":"The OPTIMA study, buprenorphine\/naloxone and methadone models of care for the treatment of prescription opioid use disorder: study design and rationale.","volume":"69","author":"Socias","year":"2018","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"ioi260005r28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1360-0443.2006.01321.x","article-title":"Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study.","volume":"101","author":"Fischer","year":"2006","journal-title":"Addiction"},{"issue":"24","key":"ioi260005r29","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure.","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"ioi260005r30","doi-asserted-by":"publisher","first-page":"10481","DOI":"10.1080\/14767058.2022.2130238","article-title":"Comparison of neonatal outcomes in pregnant women undergoing medication-assisted treatment of opioid use disorder with methadone or buprenorphine\/naloxone.","volume":"35","author":"Petrich","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ioi260005r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2025.112632","article-title":"Buprenorphine-naloxone versus buprenorphine for opioid use disorder during pregnancy: a systematic review and meta-analysis.","volume":"271","author":"de Lima","year":"2025","journal-title":"Drug Alcohol Depend"},{"issue":"25","key":"ioi260005r32","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1056\/NEJMoa2214470","article-title":"Eat, sleep, console approach or usual care for neonatal opioid withdrawal.","volume":"388","author":"Young","year":"2023","journal-title":"N Engl J Med"},{"key":"ioi260005r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108765","article-title":"\u201cYou have to take this medication, but then you get punished for taking it:\u201d lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period.","volume":"139","author":"Schiff","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"ioi260005r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2025.209681","article-title":"Prenatal opioid use disorder and child protective service involvement: does consistent treatment matter?","volume":"172","author":"Wang","year":"2025","journal-title":"J Subst Use Addict Treat"},{"key":"ioi260005r35","doi-asserted-by":"publisher","DOI":"10.1089\/bfm.2025.0045","author":"Nelson-Rodriguez","year":"2025","journal-title":"Breastfeeding Med"},{"issue":"6","key":"ioi260005r36","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/annonc\/mdx043","article-title":"Statistical controversies in clinical research: value of adverse events relatedness to study treatment: analyses of data from randomized double-blind placebo-controlled clinical trials.","volume":"28","author":"Le-Rademacher","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"ioi260005r37","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/annonc\/mdy035","article-title":"Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events-a meta-analysis.","volume":"29","author":"Trone","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"ioi260005r38","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1097\/CCM.0000000000006031","article-title":"Effectiveness of sublingual buprenorphine for pain control in the ICU.","volume":"51","author":"Patanwala","year":"2023","journal-title":"Crit Care Med"},{"issue":"6","key":"ioi260005r39","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1017\/S0033291720000525","article-title":"Buprenorphine: prospective novel therapy for depression and PTSD.","volume":"50","author":"Madison","year":"2020","journal-title":"Psychol Med"},{"issue":"8","key":"ioi260005r40","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/add.14636","article-title":"Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.","volume":"114","author":"Frost","year":"2019","journal-title":"Addiction"},{"issue":"5","key":"ioi260005r41","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1542\/peds.79.5.706","article-title":"Head circumference reference data: birth to 18 years.","volume":"79","author":"Roche","year":"1987","journal-title":"Pediatrics"},{"issue":"1","key":"ioi260005r42","doi-asserted-by":"publisher","first-page":"59.e1","DOI":"10.1016\/j.ajog.2024.12.001","article-title":"Association between buprenorphine dose and outcomes among pregnant persons with opioid use disorder.","volume":"233","author":"Jarlenski","year":"2025","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"ioi260005r43","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1542\/peds.2015-2651","article-title":"The Apgar score.","volume":"136","author":"AMERICAN ACADEMY OF PEDIATRICS COMMITTEE ON FETUS AND NEWBORN","year":"2015","journal-title":"Pediatrics"},{"issue":"5","key":"ioi260005r45","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/AOG.0b013e3181a09fc0","article-title":"Overview of maternal morbidity during hospitalization for labor and delivery in the United States: 1993-1997 and 2001-2005.","volume":"113","author":"Berg","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"9","key":"ioi260005r46","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1080\/10826084.2022.2083174","article-title":"Buprenorphine compared with methadone in pregnancy: a systematic review and meta-analysis.","volume":"57","author":"Kinsella","year":"2022","journal-title":"Subst Use Misuse"},{"issue":"3","key":"ioi260005r47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40264-022-01267-z","article-title":"Comparative safety analysis of opioid agonist treatment in pregnant women with opioid use disorder: a population-based study.","volume":"46","author":"Wang","year":"2023","journal-title":"Drug Saf"},{"issue":"9453","key":"ioi260005r48","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d.","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"ioi260005r24","author":"Squires","year":"2009"},{"key":"ioi260005r18","unstructured":"American Society of Addiction Medicine. About the ASAM Criteria. Accessed November 16, 2025. https:\/\/www.asam.org\/asam-criteria\/about-the-asam-criteria"},{"key":"ioi260005r19","unstructured":"Substance Abuse and Mental Health Services Administration. Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. January 2018. Accessed November 16, 2025. https:\/\/library.samhsa.gov\/product\/clinical-guidance-treating-pregnant-and-parenting-women-opioid-use-disorder-and-their"},{"key":"ioi260005r44","doi-asserted-by":"crossref","unstructured":"Osterman? MJ. Changes in primary and repeat cesarean delivery: United States 2016-2021. 2022. Vital Statistics Rapid Release; no.21. https:\/\/stacks.cdc.gov\/view\/cdc\/117432","DOI":"10.15620\/cdc:117432"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2846277\/jamainternal_winhusen_2026_oi_260005_1777045086.5433.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:01:04Z","timestamp":1777906864000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2846277"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2026.0057","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}